🔗 Share this article

Given that the US undertakes sweeping changes to its immunization schedules, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by questioning Covid vaccines during the global health crisis and has focused upon possible fatalities after Covid vaccination in her short tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Program

Health officials had intended to announce major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of step with a large portion of the global community with little proof for improved outcomes. This reveal has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth individual to run the center this year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing specific pediatric vaccine recommendations in the US to become more like the Danish model, a nation with comprehensive healthcare and a population approximately the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no apparent track record in pharmaceutical research, oversight or leadership, which has been typical for past leaders of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a major agency. She lacks background in industry regulation.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that previous people who headed CBER have had.”

CDER has an immense portfolio at the agency, she pointed out.

“Everybody just pays attention on the new drug program, but the generic drug division authorizes a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and more, and all of those need to be looked after,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative aspect to the job, which supervises over 5,000 staff members. “It is a massive management job, if you execute it properly,” she added.

Agency Reaction and Contentious Policies

When asked about concerns about Høeg’s fitness for the role and whether this selection signifies greater collaboration among agency officials on immunizations, a representative responded that the “concerns are based on flawed premises”.

“Her resume is consistent with the functions of her job,” the representative stated, pointing to the months Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's controversial expedited review system, a contentious one-day therapy clearance system that reportedly worried her former heads. “How are these medications being picked for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of confidentiality going on at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, except for vaccines.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if concerning, past, Howard observe. She published a study using unconfirmed public submissions to estimate the rate of heart inflammation after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the new government included revising rules for new vaccines and discontinuing “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Høeg has reportedly floated the idea of preventing teenage boys from getting COVID-19 vaccines.

“She’s an complete dogmatist who starts off with her conclusions and tailors the evidence to fit the evidence in a very deceptive, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|